相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The emerging role of epigenetic therapeutics in immuno-oncology
Michael J. Topper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Bareche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma
Anusha Kalbasi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
Oscar M. Rueda et al.
NATURE (2019)
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
Camilla Salvagno et al.
NATURE CELL BIOLOGY (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer
Jaclyn Sceneay et al.
CANCER DISCOVERY (2019)
Harnessing innate immunity in cancer therapy
Olivier Demaria et al.
NATURE (2019)
PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy
Xudong Zhang et al.
ADVANCED MATERIALS (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
Tamara Maes et al.
CANCER CELL (2018)
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Wanqiang Sheng et al.
CELL (2018)
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Li Tang et al.
NATURE BIOTECHNOLOGY (2018)
Engineering PD-1-Presenting Platelets for Cancer Immunotherapy
Xudong Zhang et al.
NANO LETTERS (2018)
ERVmap analysis reveals genome-wide transcription of human endogenous retroviruses
Maria Tokuyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Anje Cauwels et al.
CANCER RESEARCH (2018)
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Chao Wang et al.
NATURE BIOMEDICAL ENGINEERING (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn et al.
CELL (2016)
IL-6 pathway in the liver: From physiopathology to therapy
Dirk Schmidt-Arras et al.
JOURNAL OF HEPATOLOGY (2016)
Antitumour actions of interferons: implications for cancer therapy
Belinda S. Parker et al.
NATURE REVIEWS CANCER (2016)
Anticancer Platelet-Mimicking Nanovehicles
Quanyin Hu et al.
ADVANCED MATERIALS (2015)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
Nanoparticle biointerfacing by platelet membrane cloaking
Che-Ming J. Hu et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression
Giulia Escobar et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
Nanoparticle-detained toxins for safe and effective vaccination
Che-Ming J. Hu et al.
NATURE NANOTECHNOLOGY (2013)
Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression
Vanja Sisirak et al.
CANCER RESEARCH (2012)
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
Bradley N. Bidwell et al.
NATURE MEDICINE (2012)
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Che-Ming J. Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Annexin A1 regulates TGF-β signaling and promotes metastasis formation of basal-like breast cancer cells
Marjo de Graauw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis
Christoph Domschke et al.
CANCER RESEARCH (2009)
Impaired interferon signaling is a common immune defect in human cancer
Rebecca J. Critchley-Thorne et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis
Michele De Palma et al.
CANCER CELL (2008)
The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
Audrey L. Kinter et al.
JOURNAL OF IMMUNOLOGY (2008)
Nanoparticle-mediated cellular response is size-dependent
Wen Jiang et al.
NATURE NANOTECHNOLOGY (2008)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
分享论文
